Luminex-based virtual crossmatching for renal transplantation in South Africa.
Human leukocyte antigens (HLA) are a highly polymorphic system of glycoproteins that have a functional role in the presentation of peptides to the immune system. (1,2) HLA class I molecules are expressed on most nucleated cells, while HLA class II antigens are generally found on professional antigen-presenting cells. (3) HLA class II antigens can also be upregulated on kidney cells. (4) As a highly polymorphic system, however, specific HLA alleles can become the targets of antibody responses in people sensitised to foreign HLA molecules during pregnancy, transfusion of blood products, or organ transplantation. (1,5,6) Humoral responses or sensitisation to HLA are major barriers to solid organ transplantation. (1,7) Sensitised patients are more likely to crossmatch positive with potential donors and have a reduced chance of receiving a renal transplant. (8) The detection of anti-HLA antibodies helps to predict both the function and survival of transplant allografts. (9) Most allograft damage is mediated though the activation of complement; C4d deposition is widely accepted as a marker for antibody-mediated rejection in renal allografts. (10)
Detection of anti-HLA antibodies
In the Johannesburg renal transplantation programme, recipient placement on the waiting list for cadaveric kidney allocation is determined by a composite score comprising length of time on the waiting list, recipient age, and the percentage of panel-reactive antibodies (PRAs, an estimate of the percentage of HLA types in the general population against which the recipient has antibodies). Laboratory testing before transplantation includes crossmatching donor cells (lymphocytes as surrogates of renal cells) with recipient serum. If a recipient has antibodies against a donor's HLA type, the antibodies will bind to the donor's cells and the crossmatch should be positive, whereas if the recipient does not have antiHLA donor-specific antibodies, the crossmatch should be negative. The Johannesburg renal transplant programme currently performs a transplant based on both a negative complement-dependent cytotoxicity (CDC) and the more sensitive flow cytometric crossmatch. However, both can be subject to interference, (8,11) and even if both crossmatches are negative, early graft rejections still occur. Higher organ rejection rates occur among patients with donor-specific anti-HLA antibodies prior to transplantation. (9) Re-evaluation of the algorithm of laboratory-based testing is therefore critical to provide a comprehensive work-up before transplantation.
Acute allograft rejection is currently diagnosed by percutaneous needle biopsy of the renal allograft. (12) Acute antibody-mediated rejection is a sequential process; initial endothelial damage by donor-specific anti-HLA antibodies is followed much later by histological alterations (such as C4d deposition and significant interstitial infiltration) and clinical manifestations (graft dysfunction and rejection). (12-14) Detecting donor-specific anti-HLA antibodies has several clinical applications, e.g. predicting transplant success (1,11,15,16) and helping to streamline organ allocation particularly for highly sensitised patients (who often crossmatch positive against multiple donors and spend long periods on waiting lists). (1,14)
Single-antigen technology is used to detect HLA antibodies
The Luminex anti-HLA antibody detection assay is reportedly more sensitive and specific than either the CDC or flow cytometric crossmatches. (5,9,15) In fact, some consider the Luminex antibody detection technique to be the new gold standard for identifying anti-HLA antibodies. (6) This technique is a solid-phase assay in which purified HLA molecules (either of a single HLA type or a combination of types) are attached to beads. These molecules will bind to anti-HLA antibodies in the patient's serum. (1,15) Using single-antigen technology, the Luminex technology can predict a patient's sensitisation to particular HLA types prior to transplantation without performing a physical CDC or flow cytometric crossmatch (termed a 'virtual crossmatch'). (5,6,15)
In this retrospective study, we compared Luminex virtual crossmatch predictions with the flow cytometric crossmatch results. In the patients who received transplants, Luminex virtual crossmatch predictions were also compared with short-term (6-month) renal graft success. The importance of technological advances in laboratory-based testing in assessing the risk of antibody-mediated rejection in renal transplantation is highlighted.
We aimed to determine whether Luminex anti-HLA antibody analysis could accurately predict flow cytometric crossmatch outcomes and whether Luminex antibody detection could predict clinical short-term graft success. We hypothesised that in identifying donor-specific anti-HLA antibodies before transplantation, this solid-phase approach could ensure more efficient organ allocation and accurately determine acceptable donor-recipient combinations.
Materials and methods
Sera were obtained from 64 recipients who were routinely crossmatched against either cadaveric or related living donors (September 2009--August 2010). These were stored at -70[degrees]C prior to antibody testing. Ethics approval for this study was obtained from the Human Research Ethics Committee of the University of the Witwatersrand (HREC M090331). Donor HLA typing was performed by the South African National Blood Service as routine patient work-up.
Luminex single-antigen beads coated with HLA antigens (GenProbe, USA) were incubated with recipient sera in a 96-well plate in the dark on a rotating platform. After washing, phycoerythrin-conjugated goat anti-human IgG (Gen-Probe, USA) was added which would bind to recipient HLA antibodies captured on the beads. The test and control samples were then acquired using the Luminex Flow Analyzer and Luminex' 100 IS[TM] version 2.3 software (Luminex, USA). The Quicktype for Lifematch 2.5.2 software (Gen-Probe, USA) was used to interpret results. All assays included manufacturer's positive and negative control sera and were prepared according to the GenProbe, USA, instructions. (17)
To determine whether an individual single-antigen bead was positive (i.e. if recipient anti-HLA antibody was bound to the bead), the mean fluorescence intensity (MFI) of the bead was divided by the MFI of the three negative control beads. The background adjustment factor was subtracted from this value to provide three different adjusted values. A bead was considered to be positive if two or more of the adjusted values were positive. (17) MFIs of ~1 000 or more were generally considered as positive, although each case was analysed individually and pattern reactivity was also taken into consideration; three recipients had antibody testing performed on their post-transplant sera following documented organ rejection.
Recipient sera were routinely crossmatched with ABO bloodgroup-compatible donor T and B lymphocytes, with 111 T- and B-cell flow cytometric crossmatches being performed between 64 recipients and 27 donors (related living and cadaveric). Some recipients were crossmatched against multiple donors. Donor lymphocytes were incubated with recipient sera for 1 hour at 37[degrees]C. Donor cells were also incubated with appropriate positive (multispecific and anti-lymphocyte globulin) and negative (AB serum and autologous donor serum) control sera. Cells were then washed, and were incubated with rabbit anti-human IgG [(Fab').sub.2] (FITC) (Dako, Denmark) for 30 minutes at 4[degrees]C to detect any bound anti-HLA antibodies. Donor lymphocytes were then washed and stained with CD19 PE (Beckman Coulter, France) and CD3 APC (BD Biosciences, USA) to stain the B and T cells, respectively. After a 15-minute incubation, 300 000 events were acquired on the LSRII flow cytometer (BD Biosciences, USA). Results were analysed using FlowJo 8.5.2 software (Treestar, USA). B-cell crossmatches were considered positive if the MFI was at least 5 times greater than the MFI of the lowest negative control. T-cell crossmatches were considered positive if the MFI was at least 1.5 times greater than the MFI of the lowest negative control.
Sensitivity, specificity, and positive and negative predictive values of the Luminex virtual crossmatch were retrospectively calculated in comparison with the flow cytometric crossmatch and with short-term graft outcomes. A Mann-Whitney test was performed to compare the MFIs of single-antigen beads between positive and negative flow cytometric crossmatches.
Luminex anti-HLA antibody testing compared with flow cytometric crossmatch results
For 111 crossmatches performed on 64 recipients, the sensitivity, specificity, positive and negative predictive values for predicting the T-cell crossmatch were 85.7%, 90.7%, 57.1% and 97.8%, respectively, and for the B-cell crossmatch, 100%, 87.2%, 12.5% and 100%, respectively (Table I).
We compared the MFIs of the single-antigen beads (which predicted the flow crossmatch as positive) with actual positive or negative crossmatch results for both T (class 1) and B (class 2) cell flow cytometric crossmatches (Fig. 1). This was done to try to predict whether an MFI cut-off could be used to predict flow cytometric crossmatch outcomes. For the class 1 crossmatch, the MFIs of the single-antigen beads were significantly greater for the positive compared with the negative flow cytometric crossmatches (p < 0.0001). Similarly, the MFIs of the single-antigen beads were significantly increased in the positive compared with the negative class 2 flow cytometric crossmatches (p = 0.0007) (Fig. 1). However, although the MFIs are significantly different between positive and negative crossmatches for both class 1 and 2, there is some overlap in antibody reactivity between positive and negative flow cytometric crossmatches, which makes it difficult to determine an exact MFI cut-off for predicting flow cytometric crossmatch positivity.
Relevance of HLA antibody testing to clinical outcome
Seventeen of the 64 recipients received transplants (all B- and T-cell flow cytometric crossmatch-negative), and graft success was compared with the predictive antibody screening results. Fourteen of the 17 (82.4%) patients had successful transplants, which correlated with the Luminex prediction as HLA antibodies were not detected in these patients (Table II). However, 3 of the 17 recipients (17.6%) experienced acute rejection and graft failure/ loss (Tables II and III). For each of these 3 patients, although the flow cytometric crossmatch was negative, Luminex analysis revealed the presence of donor-specific anti-HLA antibodies in both pre- and post-transplantation sera (Table III). Luminex antibody testing was accurate in predicting short-term graft success, with both a 100% sensitivity and specificity, as well as 100% positive predictive value (PPV) and negative predictive value (NPV) values (Tables II and III).
[FIGURE 1 OMITTED]
Patients who have donor-specific anti-HLA antibodies before transplantation have poor graft outcomes, with the vast majority of cases of antibody-mediated renal graft rejection attributed to anti-HLA antibodies. (1,13,18) Solid-phase assays such as Luminex antibody testing can sensitively and specifically detect these antibodies and predict graft success, (1,11,15,16) and may be adequate to replace older crossmatch methodologies. (2,19) Our primary objective was to determine whether Luminex antibody analysis could accurately predict T- and B-cell flow crossmatches for patients awaiting renal transplantation in our setting. We used single-antigen technology which detects antibodies directed at a single HLA allele in highly sensitised individuals.
Compared with the flow cytometric crossmatch, the Luminex virtual crossmatch had a sensitivity of 85.6% for prediction of the T-cell crossmatch and a sensitivity of 100% for prediction of the B-cell crossmatch. The sensitivity for prediction of the crossmatch was lower than reported, (5,8,11,20) and we subsequently compared Luminex results with graft outcomes. Although the PPV for the Luminex virtual crossmatch was only 57.1% compared with the T-cell flow cytometric crossmatch, the PPV in comparison with transplant outcome was 100%. The Luminex antibody detection assay more reliably predicted graft failure over this period than the conventional flow cytometric assay.
The MFIs of the single-antigen beads (which predicted positive-flow cytometric crossmatches) were compared between the actual positive- and negative-flow crossmatch results. Although the MFIs were significantly different (p<0.001 for class 1 and p = 0.0007 for class 2), there was some overlap in antibody reactivity that cannot be ignored. This makes it difficult to define an absolute Luminex MFI cut-off value for predicting flow cytometric crossmatch positivity.
Although anti-HLA antibody detection assays have been criticised as being over-sensitive, (15,20) our study did not demonstrate this with the Luminex assay showing an NPV of 100% (14 patients who were successfully transplanted showed no donor-specific antiHLA antibodies). All antibodies, including 'weak' antibodies, were clinically relevant. These findings support addition of Luminex technology to routine pre-transplantation work-up and possibly supplanting the flow cytometric crossmatch assay in our laboratory. It is not clear why the flow cytometric crossmatch was negative for the 3 patients whose grafts were rejected, but the assay is subject to methodological and biological interferences such as poor donor lymphocyte viability, interfering therapeutic antibodies, autoantibodies, and non-HLA-specific antibodies confounding results. (21,22) The flow cytometric crossmatch also depends on the varying levels of skill of staff members performing the assay. (22) Since only patients who have negative crossmatches are given transplants, the PPV or NPV of the flow cytometric assay compared with graft success cannot be reported.
Other advantages of implementation of Luminex single-antigen technology include post-transplantation monitoring to predict and evaluate graft dysfunction and the ability to target specific donor-directed anti-HLA antibodies in desensitisation regimens. (1,23) The Luminex anti-HLA antibody assay also has the advantage of not requiring viable donor cells, can be performed at convenience (before the time of transplant in the case of cadaveric donation), and specifically detects HLA-directed antibodies. (15)
In this South African cohort, virtual crossmatching using Luminex single-antigen beads for detection of anti-HLA antibodies predicted clinical outcome better than flow cytometric crossmatching. Luminex technology should be routinely implemented into pre-transplantation work-up of renal transplant recipients.
Department of Haematology and Molecular Medicine, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Services, Johannesburg
Catherine M Worsley, BSc, BSc Hons, MSc
Elizabeth S Mayne, MB BCH, FCPath (Haem), MMed Path (Haem)
Melinda S Suchard, BSc, FCPath (SA) (Clin), MMed (Clin), DTM&H
Corresponding author: C M Worsley (email@example.com)
Acknowledgements. The authors especially wish to thank Patricia Wyllie and the laboratory staff at the University of the Witwatersrand Donald Gordon Medical Centre and the NHLS flow cytometry units in Johannesburg who made this study possible. We also thank Derrick Nelson of the South African National Blood Transfusion Service for donor HLA typing results, and the patients, renal transplant co-ordinators, physicians and surgeons in the Johannesburg renal transplant programme.
This work was financially supported by the NHLS Research Trust Pathology Research Development Grant 004_94095.
Authors' contributions. CMW and MSS designed the study. CMW performed the laboratory work, data analysis, and prepared the manuscript. ESM and MSS aided in preparing and reviewing the manuscript.
(1.) Zeevi A, Girnita A, Duquesnoy R. HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation. Immunol Res 2006;36:255-264.
(2.) Howell WM, Carter V, Clark B. The HLA system: immunobiology, HLA typing, antibody screening and crossmatching techniques. J Clin Pathol 2010; 63:387-390.
(3.) Shankarkumar U, Ghosh K, Mohanty D. The human leukocyte antigen (HLA) system. J Assoc Physicians India 2002;50:916-926.
(4.) Fuggle SV, McWhinnie DL, Chapman JR, Taylor HM, Morris PJ. Sequential analysis of HLA-class II antigen expression in human renal allografts--induction of tubular class II antigens and correlation with clinical parameters. Transplantation 1986;42:144-149.
(5.) Vaidya S, Partlow D, Susskind B, Noor M, Gugliuzza K. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead Luminex assay. Transplantation 2006;82:1524-1528.
(6.) Gebel HM, Moussa O, Eckels DD, Bray RA. Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums. Hum Immunol 2009;70:610-617.
(7.) Patel R, Terasaki P. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-739.
(8.) Bingaman AW, Murphey CL, Palma-Vargas J, Wright F. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008;86:1864-1868.
(9.) Zeevi A, Lunz JG III, Shapiro R, et al. Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum Immunol 2009;70:645-650.
(10.) Murata K, Baldwin WM. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody mediated rejection. Transplantation Review (Orlando) 2009;23:139-150.
(11.) Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007;7:626-632.
(12.) Hartono C, Muthukumar T, Suthanthiran M. Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant 2010;15:35-41.
(13.) Cai J, Terasaki PI. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 2008;20:602-606.
(14.) Bogman MJ, Dooper IM. Banff classification for the histological diagnosis of renal graft rejection: what are the advantages? Nephrol Dial Transplant 1995;10:1291-1293.
(15.) Tait BD, Hudson F, Cantwell L, et al. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology 2009;14:247-254.
(16.) Lee P-C, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002;74:1192-1194.
(17.) http://www.tepnel.com/docs/content.asp?ID=1 (accessed 2 May 2011).
(18.) Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009;70:589-594.
(19.) Colombo MB, Haworth SE, Poli F, et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clinical Cytometry 2007;728:465-471.
(20.) Amico P, Honger G, Steiger J, Schaub S. Utility of the virtual crossmatch in solid organ transplantation. Current Opinion in Organ Transplantation 2009;14:656-661.
(21.) Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008;69:591-604.
(22.) Poli F, Cardillo M, Scalamogna M. Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach. Hum Immunol 2009;70:631-635.
(23.) Marrari M, Duquesnoy RJ. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transplant Immunol 2010;22:105-109.
Accepted 27 September 2011.
Table I. Evaluation of the Luminex virtual crossmatch N TP TN FN FP Sensitivity (%) T-cell crossmatch (HLA class 1) 111 12 88 2 9 85.7 B-cell crossmatch (HLA class 2) 111 2 95 0 14 100 Specificity PPV NPV (%) (%) (%) T-cell crossmatch (HLA class 1) 90.7 57.1 97.8 B-cell crossmatch (HLA class 2) 87.2 12.5 100 TP = true positive; TN = true negative; FN = false negative; FP = false positive; PPV = positive predictive value; NPV = negative predictive value. Table II. Comparison of Luminex antibody predictions with renal graft success N TP TN FN FP Sensitivity (%) Specificity (%) 17 3 14 0 0 100 100 N PPV (%) NPV (%) 17 100 100 TP = true positive; TN = true negative; FN = false negative; FP = false positive; PPV = positive predictive value; NPV = negative predictive value. Table III. Renal allograft rejection cases Case 1 Case 2 Patient history 31-year-old male 31-year-old male Previous transplant rejection Living related or Living related Cadaver cadaver donor Post-transplant <2 weeks <5 days time to rejection Nephrectomy Yes Yes Histological Acute rejection Acute humoral diagnosis (C4d staining rejection negative) (C4d staining positive) Donor HLA type A*03,32 A*02,24 B*15,44 B*07,35 DR*04(53),16(51) DR*04(53),15(51) Luminex antibody DR*51 (pre 6 342, A*02 (pre 1 279, results and post 3 169) post 848) strengths (MFI) B*07 (pre 1 443, post 2 124) DR*04 (pre 1 439, post 1 778) Case 3 Patient history 50-year-old female Living related or Cadaver cadaver donor Post-transplant <2 days time to rejection Nephrectomy Yes Histological Delayed hyperacute diagnosis vascular rejection (C4d staining not performed) Donor HLA type A*02,11 B*07,15 DR*04(53),13(52) Luminex antibody B*15 (pre 1 936, results and post 1 745) strengths (MFI) DR*04 (pre not detected, post 3 344) pre = pre-transplantation; post = post-transplantation.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Articles|
|Author:||Worsley, Catherine M.; Mayne, Elizabeth S.; Suchard, Melinda S.|
|Publication:||South African Medical Journal|
|Date:||Jan 1, 2012|
|Previous Article:||Traumatic rhabdomyolysis (crush syndrome) in the rural setting.|
|Next Article:||Provision and need of HIV/AIDS services in the city of Tshwane Metropolitan Municipality, 2010.|